This brief commentary seeks to develop the analysis of Daniels, Porteny and Urrutia of the implications of expansion of the scope of health technology assessment (HTA) beyond issues of safety, efficacy, and cost-effectiveness. Drawing in particular on experience in the United Kingdom, it suggests that such expansion can be understood not only as a response to the problem of insufficiency of evidence, but also to that of legitimacy. However, as expansion of HTA also renders it more visibly political in character, it is plausible that its legitimacy may be undermined, rather than enhanced by, independence from the policy process
The new regulatory governance perspective has introduced several insights to the study of health tec...
Healthcare innovations often represent important improvements in population welfare, but at what cos...
How do we assess the impact of Health Technology Assessment (HTA)? Whilst high-income countries (HIC...
All societies face the need to make judgments about what interventions (both public health and perso...
Daniels, Porteny and Urrutia et al make a good case for the idea that that public decisions ought to...
Abrishami, Oortwijn, and Hofman (AOH) attribute to me a position I do not hold and an argument I did...
In the editorial published in this journal, Daniels and colleagues argue that his and Sabin’s accoun...
The article by Daniels and colleagues on expanding the scope of health technology assessment (HTA) t...
The accountability for reasonableness (AFR) concept has been developed and discussed for over two de...
There are at least two reasons why health technology assessment (HTA) agencies need to ...
When making recommendations about the public funding of new health technologies, policy makers typic...
Embedding health technology assessment (HTA) in a fair process has great potential to capture societ...
With their article, Grutters et al raise an important question: What do successful health technology...
An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on rel...
Cost-effectiveness analysis (CEA) plays a key role informing decision-making in healthcare and, cons...
The new regulatory governance perspective has introduced several insights to the study of health tec...
Healthcare innovations often represent important improvements in population welfare, but at what cos...
How do we assess the impact of Health Technology Assessment (HTA)? Whilst high-income countries (HIC...
All societies face the need to make judgments about what interventions (both public health and perso...
Daniels, Porteny and Urrutia et al make a good case for the idea that that public decisions ought to...
Abrishami, Oortwijn, and Hofman (AOH) attribute to me a position I do not hold and an argument I did...
In the editorial published in this journal, Daniels and colleagues argue that his and Sabin’s accoun...
The article by Daniels and colleagues on expanding the scope of health technology assessment (HTA) t...
The accountability for reasonableness (AFR) concept has been developed and discussed for over two de...
There are at least two reasons why health technology assessment (HTA) agencies need to ...
When making recommendations about the public funding of new health technologies, policy makers typic...
Embedding health technology assessment (HTA) in a fair process has great potential to capture societ...
With their article, Grutters et al raise an important question: What do successful health technology...
An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on rel...
Cost-effectiveness analysis (CEA) plays a key role informing decision-making in healthcare and, cons...
The new regulatory governance perspective has introduced several insights to the study of health tec...
Healthcare innovations often represent important improvements in population welfare, but at what cos...
How do we assess the impact of Health Technology Assessment (HTA)? Whilst high-income countries (HIC...